Browsing by Author "Pak Y."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party
    (2008) Kilciksiz S.; Celik O.K.; Pak Y.; Demiral A.N.; Pehlivan M.; Orhan O.; Tokatli F.; Agaoglu F.; Zincircioglu B.; Atasoy B.M.; Ozseker N.; Yersal O.; Niang U.; Haydaroglu A.
    To identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (RT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (RT) alone while 38 of them (47.5%) were treated with surgery (S) and RT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of >50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at ≥50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT ± S. Progression to MM remains as the main problem especially for older patients. © 2008 Wiley-Liss, Inc.
  • No Thumbnail Available
    Item
    Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey
    (2008) Demiral A.N.; Alicikus Z.A.; Işil Ugur V.; Karadogan I.; Yöney A.; Andrieu M.N.; Yalman D.; Pak Y.; Aksu G.; Özyigit G.; Özkan L.; Kilçiksiz S.; Koca S.; Çaloǧlu M.; Yavuz A.A.; Başak Çaǧlar H.; Beyzadeoǧlu M.; Iǧdem S.; Serin M.; Kaplan B.; Koç M.; Korkmaz E.; Karakoyun-Çelik O.; Dinçer S.; Kinay M.
    Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were "≥ IB" disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. © 2008 Elsevier Inc. All rights reserved.